Shares in Novavax have soared 2,781% since the start of the year on hopes for its Covid-19 vaccine PHOTO: AFP via Getty Images
The EU has already signed a deal to buy up to 200 million doses of the two-shot vaccine pending approval by the Amsterdam-based watchdog.Chief executive Stanley Erck said the firm “looks forward to providing an additional vaccine option in Europe, built on a proven, well-understood technology platform”.
Novavax’s so-called protein subunit technology is already tried and tested, having been used for decades to vaccinate people against diseases including hepatitis B and whooping cough. By contrast, the Pfizer-BioNTech and Moderna vaccines have dominated the global Covid response using pioneering, but hitherto largely untested Messenger RNA technology.
Rare but serious side effects of heart inflammation have been reported with the mRNA vaccines, and blood clots with the viral vector vaccines.
Technology Technology Latest News, Technology Technology Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: GuardianNigeria - 🏆 1. / 94 Read more »
Source: GuardianNigeria - 🏆 1. / 94 Read more »